Ingrain Health

Ingrain is a biotechnology company launched by Flagship Pioneering that focuses on developing a new class of medicines targeting the enteric nervous system (ENS), often referred to as the "second brain." By leveraging the ENS's extensive network of neurons and its role in systemic health, the company aims to treat chronic conditions across gastrointestinal, metabolic, and inflammatory therapeutic areas. Ingrain utilizes a proprietary platform to map ENS signaling and identify novel targets for small molecule modulation. The company's approach represents a shift toward treating systemic diseases through the gut-brain axis and neural regulation of organ function.